Brenus Pharma
It develops immunotherapies aimed at hard-to-treat solid tumours, focusing on oncology indications with limited treatment options.
Overview
Brenus Pharma is a biotechnology company advancing immunotherapy programs for hard-to-treat solid tumours. Its work targets oncology markets where patients have limited effective treatment options, positioning the company within cancer therapeutics rather than AI software. The company raised a €11 million Series A extension, reported as $13 million in total funding across one round. The financing is intended to advance its immunotherapy pipeline and support further development in solid-tumour oncology.
Funding History
Brenus Pharma raises €11 million Series A extension to advance immunotherapy for hard-to-treat solid tumours
Frequently Asked Questions
- How much funding does AI Funding track for Brenus Pharma?
- AI Funding tracks $13M for Brenus Pharma across 1 funding round in this database.
- Who are Brenus Pharma's investors?
- Brenus Pharma's investors include CACF Capital Innovation), Noshaq, BIO JAG.
- What does Brenus Pharma do?
- Brenus Pharma is a biotechnology company advancing immunotherapy programs for hard-to-treat solid tumours. Its work targets oncology markets where patients have limited effective treatment options, positioning the company within cancer therapeutics rather than AI software. The company raised a €11 million Series A extension, reported as $13 million in total funding across one round. The financing is intended to advance its immunotherapy pipeline and support further development in solid-tumour oncology.
- Where is Brenus Pharma headquartered?
- Brenus Pharma is headquartered in Lyon, France.
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.